B of A Securities Maintains Buy on Regenxbio, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 46.3%

Neg 46.3% Neu 0% Pos 0%

B of A Securities analyst Geoff Meacham maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $25 to $14.